. Author manuscript; available in PMC: 2019 Jul 1.

Published in final edited form as: PET Clin. 2018 Jul;13(3):423–435. doi: 10.1016/j.cpet.2018.02.010

Table 1.

Summary of current clinical trials with PET and SPECT radiotracers targeting HER2 and HER3-positive breast cancer in 2017. BC: breast cancer. MBC: metastatic breast cancer. IMPACT: IMaging PAtients for Cancer Drug selection.

⁶⁴Cu-DOTA-Patritumab ⁸⁹Zr-DFO-Lumretuzumab	RO, PK, and Treatment Response Treatment Response	NCT01479023 NCT01482377	Washington University School of Medicine Hoffmann-La Roche	Terminated Completed
⁸⁹Zr-DFO-Trastuzumab	HER2+ BC HER2+ MBC IMPACT-MBC	NCT02065609 NCT02286843 NCT01957332	Washington University School of Medicine Memorial Sloan Kettering Cancer Center University Medical Center Groningen	Recruiting Recruiting Recruiting
⁸⁹Zr-DFO-Pertuzumab	HER2+ MBC HER2+ MBC	NCT03109977 NCT02286843	Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center	Completed Recruiting
⁶⁴Cu-DOTA-Trastuzumab	Treatment Response in HER2+ BC HER2+ BC	NCT02827877 UMIN000017446	City of Hope Medical Center P-DIRECT	Recruiting Completed
¹⁷⁷Lu-DOTA-Trastuzumab	HER2+ BC Healthy Patients and HER2+ BC HER2+ MBC	Bhusari et al. NCT02683083 NCT01304797	PGIMER Camel-IDS NV Merrimack Pharmaceuticals	Completed Recruiting Ongoing, Not Recruiting
[¹³¹I]-SGMIB Anti-HER2 VHH1
⁶⁴Cu-MM-302